The development of biological agents specifically inhibiting the IL-5 pathway provided the opportunity to treat EGPA by targeting one of the crucial regulators of eosinophils, reducing the GC dose ...

Shares of Coherus BioSciences rose 4.5% to $1.8 in pre-market activity after it released positive med-stage results for its ...

Researchers identify a pathogenic subset of CD8+ memory T-cells that promote airway tissue inflammation and recurrent ...

The three-signal paradigm tries to capture how the innate immune system instructs adaptive immune responses in three well-defined actions: (1) presentation of antigenic peptides in the context of MHC ...

emory.edu Background The extent to which numerous strains of genetically engineered mice, including mice lacking Toll-like receptor 5 (T5KO), display colitis is environment dependent ... Consequently, ...

In a phase 2 clinical trial, researchers examined baricitinib and NB-UVB in adults with severe vitiligo in the dermatology ...

We recently compiled a list of the 12 Stocks Under $5 With Biggest Upside Potential. In this article, we are going to take a ...

The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active ...

A simple, noninvasive nasal swab identified a predominance of T2-low asthma subtypes in racial and ethnic minority pediatric ...

According to Future Market Insights, the global nasal allergy treatment market is poised for substantial growth, with its valuation expected to double from USD 6.6 billion in 2022 to USD 13.3 billion ...

Lilly has also submitted marketing applications for Mirikizumab-mrkz in Crohn’s disease around the globe, including in the ...

Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response ...